IRLAB Therapeutics AB (IRLAB-A.ST)

1.71SEK -2.84% (-0.05)

Over 5Y: -97.1%

2026-08-27
20 40 60
2021 2022 2023 2024 2025 2026

Figures as at 2024-12-31, reported in SEK. The newest fact in the filings is dated 2025-01-01, 604 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

3.0
OE margin -69.5%
Oper. margin -79.4%
Accruals -12.9%
FCF margin -69.5%
OCF margin -69.3%
Profit margin -87.8%
ROA -61.0%
ROCE -207.7%
ROE -254.7%
EBITDA margin —
Gross margin —
OCF / EBIT —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

0.5
RPO / sales —
RPO growth —
Segment HHI —

0 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

3.5
ND/EBITDA —
Debt / Eq 0.0×
Debt payback 0.0 yr
Cash runway 1.0 yr
Quick ratio 0.8×
Cash / Debt —
F-score —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

10.0
Sales/sh Y/Y +1566.6%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —
Sales Q/Q —
Shares change —

1 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.